The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004

Changes over time for: SCHEDULE 2

Version Superseded: 01/03/2016

Alternative versions:

Status:

Point in time view as at 14/02/2014.

Changes to legislation:

The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004, SCHEDULE 2 is up to date with all changes known to be in force on or before 06 November 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.

Changes to Legislation

Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.

Regulation 3

SCHEDULE 2E+WDRUGS [F1OR] MEDICINES TO BE ORDERED ONLY IN CERTAIN CIRCUMSTANCES

Textual Amendments

F1Word in Sch. 2 heading substituted (14.2.2014) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(a)

Commencement Information

I1Sch. 2 in force at 1.4.2004, see reg. 1(1)

Column 1	Column 2	Column 3
Drugs	Patient	Condition
In this Schedule— [F2“at-risk” means an adult or child patient or a patient aged 13 years or older who— (a) has chronic respiratory disease (including asthma and chronic obstructive pulmonary disease); (b) has significant cardiovascular disease, excluding an adult or child patient who has hypertension only; (c) has chronic renal disease; (d) is immunocompromised; (e) has diabetes mellitus; or (f) is aged 65 years or over;] [F2“child” means any person under the age of 16 years;] “EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992(4) as adjusted by the Protocol signed at Brussels on 17th March 1993(5) and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994(6); “EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland. [F3“Pandemic influenza” means influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza;] [F2“patient” has the same meaning as in the National Health Services (General Medical Services Contracts) (Wales) Regulations 2004;] [F2“residential care establishment” means a place where persons reside on a long-term basis in order to receive continuing care.]
Clobazam	Any patient	Treatment of epilepsy
Cyanocobalamin Tablets	A patient who is a vegan or who has a proven vitamin B12 deficiency of dietary origin	Treatment or prevention of vitamin B12 deficiency
Locabiotal Aerosol	Any patient	Treatment of infections and inflammation of the oropharynx
Niferex Elixir 30ml Paediatric Dropper Bottle	Infants born prematurely	Prophylaxis and treatment of iron deficiency
Nizoral Cream	Any patient	Treatment of seborrhoeic dermatitis and pityriasis versicolor
[F4Oseltamivir (Tamiflu)	[F5(1) A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where— (a)the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community; (b)the patient has an influenza-like illness; and (c)the patient can start therapy within 48 hours of the onset of symptoms. (2) A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where— (a)it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating; (b)the patient has an influenza-like illness; and (c)the patient can start therapy within 48 hours of the onset of symptoms. (3) Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Minsters.	Treatment of influenza
[F4Oseltamivir (Tamiflu)	(4) A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, where— (a)the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community; (b)the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness; (c)the patient is not effectively protected by vaccination against influenza because— (i)he has not been vaccinated because vaccination is contraindicated; (ii)he has not been vaccinated since the previous influenza season; (iii)he has been vaccinated but it has yet to take effect; or (iv)he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present; (d)the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and (e)the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness. (5) A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, where— (a)it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating; (b)the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness; (c)the patient is not effectively protected by vaccination against influenza because— (i)he has not been vaccinated because vaccination is contraindicated; (ii)he has not been vaccinated since the previous influenza season; (iii)he has been vaccinated but it has yet to take effect; or (iv)he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present; (d)the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and (e)the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness. (6) Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers.	Prophylaxis of infinfluenza]]
The following drugs for the treatment of erectile dysfunction— Alprostadil F6... Apomorphine Hydrochloride F7... Moxisylyte Hydrochloride F8... Sildenafil F9... Tadalafil F10... Thymoxamine Hydrochloride F8... Vardenafil F11...	[F12(1) The following patients with erectile dysfunction—] (a)a man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland) Act 1978(1) or the Health and Personal Social Services (Northern Ireland) Order 1972(2) for this condition with any of the following drugs— Alprostadil (Caverject), (MUSE), (Viridal) Apomorphine Hydrochloride (Uprima) Moxisylyte Hydrochloride Assembly (Erecnos) Sildenafil (Viagra) Tadalafil (Cialis) Thymoxamine Hydrochloride (Erecnos); or (b)man who is a national of an EEA State who is entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68(3) as extended by the EEA Agreement or by virtue of any other enforceable [F13EU] right who has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for this condition with any of the drugs listed in sub-paragraph (a); or (c)a man who is not a national of an EEA State but who is the member of the family of such a national who has an enforceable [F13EU] right to be treated no less favourably than the national in the provision of medical treatment and has erectile dysfunction and was being treated for that condition on 14th September 1998 with any of the drugs listed in sub-paragraph (a); or (d)a man who is suffering from any of the following— diabetes multiple sclerosis parkinson’s disease poliomyelitis prostate cancer severe pelvic injury single gene neurological disease spina bifida spinal cord injury; or (e)a man who is receiving treatment for renal failure by dialysis; or (f)a man who has had the following surgery — prostatectomy radical pelvic surgery renal failure treated by transplant [F14(g)a man who has been diagnosed as suffering severe distress resulting from erectile dysfunction where the assessment has been made by a specialist service or GP under arrangements made with a Local Health Board to provide such assessments][F15;	Treatment of erectile dysfunction
	(2) Any patient]	[F16Treatment of a condition other than erectile dysfunction, in respect of which the drug ordered is in receipt of a UK or EU marketing authorisation for the treatment of that condition]
[F4Zanamivir (Relenza)	[F17(1) A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza, where— (a)the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community; (b)the patient has an influenza-like illness; and (c)in the case of a patient— (i)who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; (ii)who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms. (2) A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza where— (a)it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or was present at the time that the virus was circulating; (b)the patient has an influenza-like illness; and (c)in the case of a patient— (i)who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; (ii)who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.	Treatment of influenza
[F4Zanamivir (Relenza)	Any patient at risk of or suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers.	Prophylaxis or treatment of influenza]]